Can Placenta Cells Save Severe COVID-19 Patients?

Pluristem CEO Claims Placenta Cell-Therapy Can Rebalance Immune Systems

Apr 20 2020

• By Sten Stovall

Listen to this article

Pluristem Therapeutics aims to start a multinational clinical trial of PLX cells for treating complications associated with COVID-19 while also helping severe patients recover from the disease under compassionate use programs in the US and Israel.

Yaky Yanay — Pluristem CEO Yanay wants to test his product ASAP in COVID-19 patients • Source: Pluristem Therapeutics Inc.

Stem cells from a newborn’s placenta could potentially heal lung tissue in severe-case COVID-19 patients by rebalancing their immune system, says Israeli firm Pluristem Therapeutics Inc.. The premise has already been successfully applied in individual cases in Israel and the US and will soon be formally studied in a multinational clinical trial, its CEO told Scrip.

Earlier this month, Haifa-based Pluristem reported that seven intensive care patients in Israeli hospitals who had been on ventilators with...

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain
Aug 22 2024
• By Alaric DeArment
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy
Aug 16 2024
• By Alaric DeArment
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
Jul 04 2024
• By Elizabeth Cairns
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Stock Watch: Thoroughly Moderna Missteps
Jun 18 2024
• By Andy Smith
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj